Abstract
Background & Aims: FALCON 1 was a phase IIb study of pegbelfermin in patients with non-alcoholic steatohepatitis (NASH) and stage 3 fibrosis. This......
小提示:本篇文献需要登录阅读全文,点击跳转登录